RASopathy Diagnosis and Management

Introduction to RASopathies

RASopathies are a group of genetic disorders caused by germline mutations in genes encoding components of the Ras/mitogen-activated protein kinase (RAS/MAPK) signaling pathway, resulting in constitutional dysregulation of this critical cellular pathway 1, 2
The American College of Medical Genetics and Genomics recommends considering RASopathy in patients with characteristic facial features, heart defects, and developmental delays 5

RASopathies result from mutations in genes that encode proteins within the RAS/MAPK pathway, which plays an essential role in regulating the cell cycle, cellular growth, differentiation, and senescence—all critical to normal development 3, 4
The National Society of Genetic Counselors notes that inheritance is typically autosomal dominant, with approximately 50% of cases arising from de novo mutations and generally complete penetrance with variable expressivity 5

The RASopathy spectrum encompasses multiple distinct but overlapping syndromes, including Neurofibromatosis type 1 (NF1), Noonan syndrome (NS), Costello syndrome (CS), Cardio-facio-cutaneous syndrome (CFC), and Legius syndrome 1, 2, 6
The American Academy of Pediatrics recommends that children with NF1 be screened for optic gliomas and neurofibromas 5

Patients with RASopathies often exhibit craniofacial dysmorphology, including hypertelorism, down-slanting palpebral fissures, and low-set ears 1, 2
The European Society of Human Genetics notes that growth abnormalities, such as proportionate short stature and relative or absolute macrocephaly, are common in RASopathies 1, 2
Cardiovascular manifestations, including congenital heart defects and aortic dilatation, are significant concerns in RASopathies 1, 2, 3, 4

The National Cancer Institute warns that most RASopathies (except Legius syndrome) carry an increased cancer risk, with children with Noonan syndrome facing approximately 8-fold increased risk for certain cancers 1, 2, 5
The American Society of Clinical Oncology recommends regular cancer surveillance for patients with RASopathies, particularly those with NF1 or Noonan syndrome 5

Molecular diagnosis through multigene RAS/MAPK pathway panel testing is recommended, with approximately 80% mutation detection rate for CFC 6, 7
The International Society for Prenatal Diagnosis notes that somatic mosaicism is well documented, particularly in NF1, and mosaic individuals may have variable to few clinical features 5

The availability of targeted therapies inhibiting the RAS-MAPK pathway has transformed management, particularly for NF1 patients with symptomatic, unresectable plexiform neurofibromas or gliomas 5, 9
The American Academy of Pediatrics recommends multidisciplinary care from specialists, including genetics, cardiology, oncology, neurology, and other subspecialties as clinically indicated 6, 7